A new 'Godzilla' fat-jab could rival Mounjaro, helping users shed a fifth of their body weight, while improving blood ...
The investigational monoclonal antibody, VYD2311, (Invivyd) met all primary and key secondary endpoints in the phase 3 LIBERTY study. It showed safety and tolerability superior to an mRNA-based ...
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the ...
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on ...
Phathom Pharmaceuticals, Inc. announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing ...
Ascletis Pharma Inc. announced positive results from a randomized, double-blind, placebo-controlled 28-day proof-of-concept clinical trial with ASC50 in mild-to-moderate plaque psoriasis patients in ...
Vanda reports a 37.1-minute placebo-adjusted advance in sleep onset in its Phase III study and plans a supplemental HETLIOZ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results